Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus have?
Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus has 105 citations in the OpenAlex counts ScholarIQ stores.
When was Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus published?
Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus has 2021 year in the ScholarIQ index.
What is the open-access status of Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus?
Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus has hybrid oa status in the ScholarIQ index.
What is the DOI of Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus?
The DOI for Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus is on the source record.
What is the PMID of Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus?
The PMID for Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus is on the source record.
What is the OpenAlex record for Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus?
The OpenAlex for Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus is on the source record.